[Shanghai Pharmaceutical: Plans to sell equity in Zeus Investment Limited and its affiliates for no less than US$199 million] On September 29, Shanghai Pharmaceuticals (601607.SH) announced that the company plans to jointly sell equity in Zeus Investment Limited and its affiliates with Primavera Capital. The enterprise value of the target company is US$397 million. After competitive bidding, Dehong Capital was the intended transferee. The equity value of the target company is expected to be no less than US$349.9 million on the delivery date, equivalent to approximately RMB 2.347 billion. The PE multiple of this transaction is 29.47. Calculated based on the corresponding equity ratio, Shanghai Pharmaceuticals is expected to obtain a transfer income of no less than US$199 million on the delivery date, equivalent to approximately RMB 1.336 billion. Compared with the purchase cost of RMB 948 million in 2016, the company will obtain greater benefits. This transaction does not constitute a related transaction or major asset restructuring. Up to now, Vitaco is mainly engaged in sports nutrition and health consumer products (such as protein powder, protein bars, sports supplements, etc.) and focuses on the local markets of Australia and New Zealand.